Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Navigating Patients' Chemotherapy Decision Making

      December 20, 2012
      By Lisa Schulmeister, RN, MN, APRN-BC, OCN, FAAN
      Publication
      Article
      Oncology Nursing NewsDecember 2012
      Volume 6
      Issue 8

      Patients considering chemotherapy treatment need to understand the risks and benefits of treatment in order to make an informed decision to undergo-or forgo-treatment.

      Lisa Schulmeister, RN, MN, APRN-BC, OCN®, FAAN

      Editor-in-Chief OncLive Nursing

      Oncology Nursing Consultant, Adjunct Assistant Professor of Nursing Louisiana State Health Sciences Center in New Orleans, Louisiana

      Patients considering chemotherapy treatment need to understand the risks and benefits of treatment in order to make an informed decision to undergo—or forgo—treatment. This decision is fairly easy to make when the treatment intent is cure, and evidence exists that the treatment is, in fact, curative. The decision to not receive chemotherapy is much more difficult to make.

      There is a fine line between hope and despair, and what is said is sometimes not heard. We have no crystal ball to tell us what the future holds for a particular patient, so we have to rely on aggregated data in our discussions about prognosis and possible treatment outcomes. Clinicians understandably tend to move quickly from talking about a poor prognosis and no chance of cure, to talking about doing something, such as palliative chemotherapy, rather than doing nothing at all. However, as we all know, there are instances where forgoing chemotherapy treatment would have been a better decision in terms of a patient’s quality of life, and even life expectancy, as sometimes treatment-related deaths do occur.

      Depending on the patient’s perspective, treatment data can be taken any number of ways. Some patients believe that they are going to be in the 10% that respond to treatment and not the 90% who do not respond. Conversely, there are patients who are told that the likelihood of experiencing a certain side effect is low and consequently anticipate that it will occur. It’s partly the “cup is either half empty or half full” perspective and partly how well the information was conveyed in the first place.

      Realistic Expectations

      In a national population cohort study of 1193 patients with metastatic lung or colorectal cancer, researchers found that 69% of the patients with lung cancer and 81% of those with colorectal cancer who were alive 4 months after diagnosis and had opted to receive chemotherapy had inaccurate expectations about the curative potential of the chemotherapy they received.1 Prior studies had found that only a minority of patients believed that palliative chemotherapy would be curative; however, in the prior studies, patients were asked only if the goal of their treatment was cure or palliation.

      In this recently published study, patients were asked how likely they thought it was that chemotherapy would cure them, and most thought that a cure was possible. After accounting for the effect of other factors, including education and income, nonwhite patients were at higher risk for having inaccurate beliefs about chemotherapy, and paradoxically, patients who reported higher scores for physician communication were at higher risk for having inaccurate chemotherapy expectations. It may be the messenger, and not the message, that patients are hearing.

      Communicating Effectively

      The study findings raise the questions of how well are we providing information on treatment intent so that patients can make informed decisions about chemotherapy treatment, and how are patients receiving and interpreting the information we provide? In addition, since most of the patients were not clear on the intent of treatment, what is the possible impact of this misunderstanding on initiating end-of-life planning and care?

      Although treatment intent is usually verbally communicated to a patient, and also often is stated on chemotherapy consent forms, data suggest that patients with advanced cancer may not understand that the chemotherapy is unlikely to be curative. I’m not suggesting that we dash all hopes of disease control or a longer life, but discussions with patients need to be clear about treatment intent. Patient navigators and nurses who provide navigation assistance may be able to improve patients’ understanding of treatment intent and guide patients to timely and appropriate care, such as earlier discussions of end-of-life wishes and earlier referral for palliative care.

      Reference

      1. Weeks JC, Catalono PJ, Cronin A, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616-1625.

      Articles in this issue

      A Surgeon's Perspective on GI Cancer Navigation
      A Life Redirected: Pursuing a Nursing Career After Osteosarcoma
      The Benefits of Genetic Testing for Cancer Survivors
      Navigating Patients' Chemotherapy Decision Making
      Sexual Health Considerations in Cancer Treatment and Survivorship
      Helping Prostate Cancer Patients to Make Informed Treatment Decisions

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman with her hair pulled back in front of a dark blue background
      Photo of a woman with her hair in a ponytail in front of a light blue background
      Image of a woman with gray hair on a light blue background
      Related Content

      Diagram of endometrial cancer

      Rx Road Map: Durvalumab for Endometrial Cancer

      Abigail T. Ramontal, MHP, MSN, APRN-FP-C
      September 12th 2025
      Article

      Photo of a woman with short hair wearing a sweater

      Where Is the Care in Health Care?

      Patricia Jakel, MN, RN, AOCN
      September 12th 2025
      Article

      Graphic depicting a nurse with a cell strucutre behind. Graphic by Gwendolyn Salas, MJH Life Sciences, with AI

      Structure to Safety: A Nurse's Guide to Safe ADC Care

      Ellen Rice Tichich, MFA, MSN, RN, NPD-BC
      September 12th 2025
      Article

      Anatomical graphic of a person with a highlighted brain tumor

      Rx Road Map: Vorasidenib for the Treatment of Astrocytoma/Oligodendroglioma

      Dalissa Tejera, MSN, APRN, ANP-C
      September 12th 2025
      Article

      Graphic resembling a seal of approval that says "FDA Approved"

      FDA Approves SIR-Spheres Y-90 Resin Microspheres for Unresectable HCC

      Bridget Hoyt
      September 12th 2025
      Article

      Photo of the FDA office's sign

      Sunvozertinib Granted FDA Accelerated Approval in EGFR Exon 20+ NSCLC

      Bridget Hoyt
      September 12th 2025
      Article
      Related Content

      Diagram of endometrial cancer

      Rx Road Map: Durvalumab for Endometrial Cancer

      Abigail T. Ramontal, MHP, MSN, APRN-FP-C
      September 12th 2025
      Article

      Photo of a woman with short hair wearing a sweater

      Where Is the Care in Health Care?

      Patricia Jakel, MN, RN, AOCN
      September 12th 2025
      Article

      Graphic depicting a nurse with a cell strucutre behind. Graphic by Gwendolyn Salas, MJH Life Sciences, with AI

      Structure to Safety: A Nurse's Guide to Safe ADC Care

      Ellen Rice Tichich, MFA, MSN, RN, NPD-BC
      September 12th 2025
      Article

      Anatomical graphic of a person with a highlighted brain tumor

      Rx Road Map: Vorasidenib for the Treatment of Astrocytoma/Oligodendroglioma

      Dalissa Tejera, MSN, APRN, ANP-C
      September 12th 2025
      Article

      Graphic resembling a seal of approval that says "FDA Approved"

      FDA Approves SIR-Spheres Y-90 Resin Microspheres for Unresectable HCC

      Bridget Hoyt
      September 12th 2025
      Article

      Photo of the FDA office's sign

      Sunvozertinib Granted FDA Accelerated Approval in EGFR Exon 20+ NSCLC

      Bridget Hoyt
      September 12th 2025
      Article

      Latest Conference Coverage

      Safety Management With Amivantamab Plus Lazertinib in NSCLC

      Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

      Adverse Events of Menin Inhibitors in AML: What Nurses Should Know

      Ivonescimab/Chemo Ups PFS After Third-Generation TKI in EGFR+ NSCLC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      259 Prospect Plains Rd, Bldg H,
      Monroe, NJ 08831

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.